

# UC San Diego

## UC San Diego Previously Published Works

### Title

Advances in non-invasive biomarkers for the diagnosis and monitoring of non-alcoholic fatty liver disease.

### Permalink

<https://escholarship.org/uc/item/6tf2v9mx>

### Authors

Long, Michelle

Gandhi, Sanil

Loomba, Rohit

### Publication Date

2020-10-01

### DOI

10.1016/j.metabol.2020.154259

Peer reviewed



Published in final edited form as:

*Metabolism*. 2020 October ; 111 Suppl: 154259. doi:10.1016/j.metabol.2020.154259.

## Advances in non-invasive biomarkers for the diagnosis and monitoring of non-alcoholic fatty liver disease

Michelle T. Long, MD, MSc<sup>1</sup>, Sanil Gandhi<sup>2</sup>, Rohit Loomba, MD, MHSc<sup>3,4</sup>

<sup>1</sup>Section of Gastroenterology, Boston Medical Center, Boston University School of Medicine, Boston, MA

<sup>2</sup>Boston University, Boston MA

<sup>3</sup>Division of Gastroenterology, Department of Medicine and Division of Epidemiology, Department of Family and Preventive, University of California at San Diego, La Jolla, CA

<sup>4</sup>NAFLD Research Center, University of California at San Diego, La Jolla, CA

### Abstract

Non-alcoholic fatty liver disease (NAFLD) is now the most common chronic liver disease in the United States, affecting approximately 1 out of every 4 Americans. NAFLD is a spectrum of disorders including simple steatosis, characterized by the presence of hepatic steatosis with minimal inflammation, and nonalcoholic steatohepatitis (NASH), characterized by the presence of hepatic steatosis with lobular inflammation, ballooning with or without peri-sinusoidal fibrosis. NASH may lead to progressive fibrosis, and therefore, Individuals with NASH and, in particular, hepatic fibrosis are at increased risk for both liver- and cardiovascular-related outcomes compared

**Correspondence:** Rohit Loomba, MD, MHSc, Director, NAFLD Research Center, Director of Hepatology, Vice-Chief, Division of Gastroenterology, Professor of Medicine, University of California at San Diego, ACTRI Building, 1W202, 9500 Gilman Drive, La Jolla, CA 92093-0887, Phone: 858-246-2201, roloomba@ucsd.edu, And, Michelle T. Long, MD, MSc, Director, Clinical Research for Section of Gastroenterology, Assistant Professor of Medicine, Boston University School of Medicine, 85 East Concord Street, Boston, MA 01742, Phone: 617-638-6525, mtlong@bu.edu.

**Author contributions:** MTL and RL conceptualized and designed the project; MTL and SG performed the literature search; MTL, SG, and RL critically reviewed the literature; MTL drafted the manuscript; RL provided critical revision of the manuscript and provided project supervision.

Declaration of Interest:

**MTL:** MTL serves as a consultant or advisory board member for Iterative Scopes and Ionis Pharmaceuticals. She receives grant support from Echosens Corp. and Gilead Sciences.

**SG:** None

**RL:** RL serves as a consultant or advisory board member for Arrowhead Pharmaceuticals, AstraZeneca, Bird Rock Bio, Boehringer Ingelheim, Bristol-Myer Squibb, Celgene, Cirus, CohBar, Conatus, Eli Lilly, Galmed, Gemphire, Gilead, Glympse bio, GNI, GRI Bio, Intercept, Ionis, Janssen Inc., Merck, Metacrine, Inc., NGM Biopharmaceuticals, Novartis, Novo Nordisk, Pfizer, Prometheus, Sanofi, Siemens, and Viking Therapeutics. In addition, his institution has received grant support from Allergan, Boehringer-Ingelheim, Bristol-Myers Squibb, Cirus, Eli Lilly and Company, Galectin Therapeutics, Galmed Pharmaceuticals, GE, Genfit, Gilead, Intercept, Grail, Janssen, Madrigal Pharmaceuticals, Merck, NGM Biopharmaceuticals, NuSirt, Pfizer, pH Pharma, Prometheus, and Siemens. He is also co-founder of Liponexus, Inc

Credit Author Statement

Michelle T. Long – Conceptualization, Data curation, Funding acquisition, Writing original draft, review & editing.

Sanil Gandhi – Data curation, Writing original draft, review & editing.

Rohit Loomba – Conceptualization, Project administration, Supervision, Writing review and editing.

**Publisher's Disclaimer:** This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

to those with steatosis alone. New treatments for NASH and hepatic fibrosis are emerging, so now, more than ever, it is important to identify individuals with more advanced disease who may be candidates for therapy. Noninvasive methods to accurately diagnosis, risk stratify, and monitor both NASH and fibrosis are critically needed. Moreover, since clinically relevant outcomes, such as developing end stage liver disease or liver cancer, take many years to develop, reliable surrogate markers of outcome measures are needed to identify and evaluate potential therapies. In this review, we discuss methods to noninvasively diagnosis and monitor both NASH and fibrosis.

---

## Introduction

Non-alcoholic fatty liver disease (NAFLD) is now the most common chronic liver disease in western societies.<sup>1, 2</sup> NAFLD is characterized by increased fatty infiltration of the liver, in the absence of secondary causes. Most patients with NAFLD have fatty infiltration of the liver without significant inflammation, so called simple steatosis, whereas approximately 20% of individuals with NAFLD have non-alcoholic steatohepatitis (NASH), which is marked by lobular inflammation, ballooning of hepatocytes and fibrosis formation.<sup>3</sup> Individuals with NASH can develop progressive fibrosis, which ultimately leads to end stage liver disease manifesting as cirrhosis, hepatocellular carcinoma, and increased risk for liver-related mortality.<sup>4, 5</sup> In addition to liver-related outcomes, individuals with NAFLD, particularly those with NASH and fibrosis, are at increased risk for cardiovascular disease, cancer, diabetes and all-cause mortality.<sup>6-9</sup>

Recently, it was noted that even early stages of hepatic fibrosis increase the risk for liver-related complications and death.<sup>5</sup> In order to prevent liver-related death, it is important to diagnosis individuals with NASH and fibrosis, when the disease is still reversible through lifestyle modification and, hopefully, through emerging therapies. For inclusion in clinical trials for NASH, most studies require biopsy confirmed NASH with a fibrosis stage of at 2 or more. Improvement and/or reversal of NASH is considered a major target of clinical trials for novel therapeutic agents aimed at lowering the burden of liver disease secondary to NAFLD.<sup>10</sup> Advanced liver fibrosis, defined by NASH clinical research network (CRN) criteria with stage 3 defined as bridging fibrosis and stage 4 as cirrhosis, is the most powerful predictor of adverse liver- and cardiovascular-related outcomes and is also considered a major target for therapeutic trials.<sup>10</sup> Therefore, NASH and fibrosis are diagnostic imperatives and the development of biomarkers to accurately diagnose and monitor NASH activity and fibrosis progress/regression are critically important.

There are many unanswered questions in the natural history of NAFLD and NASH, largely because of the challenges in diagnosis and monitoring of disease progression. The gold standard for diagnosing and monitoring NAFLD is liver biopsy.<sup>3</sup> However, liver biopsy is costly and invasive and, in clinical practice, it is not possible or appropriate to biopsy all patients with suspected NAFLD.<sup>11</sup> Though liver biopsy is considered safe, there remains a risk of serious complication, including, pain at the biopsy site, serious bleeding, and, rarely, death. Liver biopsy is also limited by variability in tissue sampling and interobserver and intraobserver variability in interpretation.<sup>12</sup> In this review, we will discuss both established and emerging non-invasive tests (NITs) for NASH and fibrosis. These biomarkers may be

useful to diagnosis disease, select patients for treatment, predicting outcomes and monitor disease activity.

### Diagnosis, risk stratification and patient selection

NAFLD is routinely identified on standard imaging techniques, such as ultrasonography (US), computed tomography (CT), and magnetic resonance imaging (MRI). Whereas the majority of those with NAFLD has simple steatosis, it is not possible to distinguish NASH from simple steatosis using imaging alone. Additionally, hepatic fibrosis, particularly if portal hypertension is not well established, is not distinguished on standard imaging techniques. A number of blood-and imaging-based NITs have been developed with great success to assist in the noninvasive diagnosis of hepatic fibrosis, though NITs for NASH are still critically needed.

**Noninvasive prediction of steatohepatitis: blood-based biomarkers**—NASH is a complex process that involves a number of disturbances including increased hepatocellular apoptosis, inflammation, oxidative stress, and altered adipokine signaling. Prior investigations have focused on identifying individual biomarkers which may reflect alterations in cellular and molecular processes in NASH. Serum aminotransferase levels, most commonly alanine aminotransferase (ALT), are often used to identify individuals with possible NASH; however, both the sensitivity and specificity for NASH are relatively low (sensitivity 64% and specificity 75%).<sup>13</sup> In a study of biopsy-confirmed NASH, over one third of participants with normal ALT (< 35 Units/Liter) had NASH or advanced fibrosis and more than half of those with elevated ALT (≥ 35 Units/Liter) did not have NASH or advanced fibrosis.<sup>14, 15</sup> The area under the receiver operating characteristic curve (AUROC) of ALT for detecting NASH is consistently poor (0.61–0.62), in multiple studies.<sup>14, 15</sup>

Apoptosis and resultant hepatocyte death and release of cytokeratin 18 (CK18) fragments is increased in NASH compared to simple steatosis. Different assays, measuring the two types of CK18 fragments, have been extensively studied as potential biomarkers to distinguish active NASH from simple steatosis. A pooled meta-analysis of 11 studies and over 800 patients showed that CK18 had a pooled sensitivity of 66% and specificity of 82%.<sup>16</sup> Using optimal cut-offs can improve sensitivity to 82% and specificity to 98%; however, there was considerable variability in how optimal cut-offs were defined between studies.<sup>16</sup> Cut-off values of CK-18 ranged widely – from 111.6–380.0 Units/Liter when maximizing sensitivity and from 261.4–670 Units/Liter when maximizing specificity.<sup>16</sup> Additional studies are needed to validate optimal CK-18 cut-offs in various populations and to determine if CK18 alone or in combination with other measures helps identify patients with likely NASH better than ALT.

Since inflammation is a hallmark feature of NASH, various inflammatory markers have been studied as potential NASH biomarkers. In the NASH Clinical Research Network, activated plasminogen activator inhibitor 1 (PAI-1) was associated with histologic NASH compared to non-NASH samples (OR 1.2, 95% confidence interval (CI) 1.08–1.34,  $p < 0.001$ ).<sup>17</sup> PAI-1 is a regulator of fibrinolysis and may contribute to both liver and vascular fibrosis.<sup>18</sup> In another study, elevation in PAI-1 was associated with a positive relationship between NASH and

fibrosis, even after adjustment for metabolic syndrome and insulin resistance.<sup>19</sup> Additional biomarkers including interleukin-8, monocyte chemoattractant protein-1, resistin, soluble interleukin-1 receptor I, soluble interleukin-2 receptor alpha, tumor necrosis factor alpha associated with histologic fibrosis, but not NASH after accounting for clinical and metabolic factors.<sup>17</sup> Markers of oxidative stress have also been tested as potential biomarkers for NASH. The oxNASH panel, which combines simple clinical and laboratory values with the ratio of 13-hydroxy octadecadenoic acid to linoleic acid (oxNASH), predicted NASH better than AST or ALT alone.<sup>20</sup> Using low and high cutoff thresholds, oxNASH had a sensitivity of 81% to exclude NASH (oxNASH below 55) and a specificity to detect NASH of 97% (oxNASH above 73), though additional validation studies are needed.<sup>20</sup> Hepatic inflammation also contributes to lipotoxicity, which also may play an important role in the progression to NASH and fibrosis.<sup>21</sup> Novel techniques using liquid chromatography/mass spectroscopy to perform lipidomic profiling of individuals with NASH compared to simple steatosis can be utilized to identify novel biomarkers.<sup>22–24</sup> In a recent proof-of-concept study, we observed that a single eicosanoid biomarker was able to distinguish NASH from simple steatosis with an AUROC of 1.<sup>22</sup> However, confirmatory studies are needed before lipidomic biomarkers can be used in clinical practice.

Fibroblast growth factor 21 (FGF21) is a hormone-like growth factor expressed in liver, adipose, and pancreas tissue, which is involved in many metabolic processes including insulin sensitivity and lipid metabolism.<sup>25</sup> FGF21 also impacts other metabolically-active hormones, including adiponectin and leptin.<sup>25</sup> Chronic exposure to FGF21 increases adiponectin levels in humans and a pegylated FGF21 analogue is currently in clinical trials as a potential treatment for NASH.<sup>26</sup> One study evaluated the role of FGF21 as a biomarker for NASH compared or combined with CK18.<sup>27</sup> Combining FGF21 and CK18 demonstrated better accuracy for NASH compared to either biomarker alone with an area under the receiver operator characteristic (AUROC) curve of 0.94 (95% CI 0.92–0.96).<sup>27</sup> Another study tested a stepwise approach starting with CK18 followed by FGF21 testing in those with high or indeterminate CK18 fragments.<sup>28</sup> This study also observed a high sensitivity and specificity for NASH; however, the majority of patients (>70%) were in the indeterminate range or had discrepant results, which limited the clinical usefulness.<sup>28</sup> Additional studies that account for comorbid metabolic conditions are needed to validate these findings. Moreover, FGF21 is regulated by genes that display circadian regulation<sup>29</sup> and FGF21 levels follow a circadian rhythm with levels fluctuating throughout the day.<sup>30</sup> Future studies should examine the potential effects of the circadian cycle and relationships to the fed/fasting state on levels of FGF21 or other possible metabolic biomarkers for NASH. Neither FGF21 nor CK18 are available for clinical use and more studies are needed before they can be widely recommended.

**Noninvasive prediction of fibrosis- blood-based biomarkers**—In contrast to NASH biomarkers, multiple biomarkers and clinical prediction models for hepatic fibrosis exist and have been extensively studied and validated as discussed in detail in a recent review paper.<sup>31</sup> The NAFLD Fibrosis Score (NFS)<sup>32</sup> and Fibrosis-4 index<sup>33</sup> (FIB4) are blood-based diagnostic models for hepatic fibrosis with high negative predictive values to exclude advanced fibrosis.<sup>34</sup> However, approximately 30% of participants will fall in the

indeterminate range of these models and both tests are limited for the diagnosis of earlier stages of fibrosis.<sup>35</sup> The FIB4 index incorporates age, ALT, aspartate aminotransferase (AST), and the platelet count into a simple formula, which was originally developed for hepatitis C and HIV co-infection.<sup>33</sup> The NFS was specifically developed for NAFLD and it uses age, body mass index (BMI), the presence of diabetes or impaired fasting glucose, AST:ALT ratio, platelet count and serum albumin in a simple online calculator ([www.naflscore.com](http://www.naflscore.com)) to predict the risk for advanced fibrosis.<sup>32</sup> The NFS performs well at excluding advanced fibrosis for those with a value below the lower cutoff of  $-1.455$  with a negative predictive value of 88%.<sup>32</sup> At the higher cutoff (0.676), the positive predictive value for advanced fibrosis was 82%.<sup>32</sup> In a recent meta-analysis, both the NFS and FIB4 had similar accuracy for detecting advanced fibrosis in NAFLD.<sup>34</sup> It is important to recognize the limitations of the NFS and FIB4 tests. The NFS and FIB4 were both derived in hospital-based samples composed of patients who had undergone liver biopsy. For example, caution is needed when applying these NITs to the general population since the scores may be miss calibrated to detect advanced fibrosis in a population with a much lower disease prevalence.<sup>36</sup> Moreover, since both NFS and FIB4 were derived from samples of middle-aged participants, different cutoffs may be needed among young participants ( $< 35$  years old) and older participants ( $\geq 65$  years old) to avoid under-diagnosis and over-diagnosis of suspected fibrosis, respectively.<sup>37</sup>

#### **Noninvasive prediction of steatohepatitis: imaging-based biomarkers—**

Imaging-based biomarkers for NASH have been evaluated in numerous studies; however, neither ultrasound- or MRI-based technologies are consistently accurate at identifying NASH.<sup>38</sup> As many individuals with NASH also have fibrosis, it is not known if elastography-based imaging techniques are measuring NASH alone or fibrosis. Large, well-phenotyped datasets of participants with NASH without fibrosis are lacking, which has limited the development of imaging biomarkers for NASH. The FibroScan-AST (FAST) score is an imaging-based biomarker panel which includes AST along with vibration-controlled elastography-derived values of fat (the controlled attenuation parameter (CAP) and the liver stiffness measurement (LSM) see next section), recently showed promise as a biomarker for “active NASH”.<sup>40</sup> The FAST score was validated in several cohorts with varying prevalence of NAFLD; however, the positive predictive value ranged from 0.33 to 0.83 depending the cohort. Additional real-world validation studies are needed as are studies evaluating the association between FAST and response to treatment.

#### **Noninvasive prediction of fibrosis: imaging-based biomarkers—**

Imaging modalities for advanced fibrosis can be divided into ultrasound- and magnetic imaging resonance (MRI)-based. The most frequently utilized ultrasound-based technology is vibration-controlled transient elastography (VCTE; FibroScan, Paris, France), which was approved by the Food and Drug Administration (FDA) in 2015. VCTE is often used in the hepatology clinic to provide point-of-care evaluation of hepatic fibrosis. VCTE uses a modified ultrasound probe that is placed in the intercostal space and delivers a 50 MHz shear wave that propagates through the liver tissue. VCTE simultaneously estimates the liver stiffness, measured in KiloPascals (kPa), which correlates with hepatic fibrosis, and the controlled attenuation parameter (CAP), measured in Decibels/meter (Db/m), which

correlates with steatosis. Multiple probe sizes are available including: the M probe (3.5 MHz), generally used in adults, the XL probe (2.5 MHz), designed for patients with central obesity, and the S probe (5 MHz), which is designed for use in children. To be considered valid, a trained operator obtains a minimum of 10 images per VCTE exam and the device automatically calculates the median LSM and CAP and the ratio of the interquartile range to median (IQR/M) LSM value. Exam quality is measured in two ways. First, all images obtained should be reviewed to ensure they are of high quality. High quality examinations should also be consistent, which is evaluated by the IQR/M value. A scan is 'very reliable' if the IQR/M  $\leq 0.10$ , 'reliable' if the IQR/M is greater than 0.1 or less than or equal to 0.3. If the IQR/M is greater than 0.3 the scan is still considered 'reliable' if the median LSM is less than 7.1 kPa, but if the LSM is greater than or equal to 7.1 KPa then the scan is considered 'poorly reliable'.<sup>41</sup> A wide range of LSM cut-off values for advanced fibrosis have been evaluated in the literature (ranging from 5.9 kPa to 12kPa) and there is considerable variability between studies.<sup>34, 42–44</sup> Additionally, the cutoff values to diagnosis advanced fibrosis may be lower on the XL probe compared to the M probe.<sup>45</sup> In a study of approximately 400 patients with biopsy-proven NAFLD, a LSM cut-off of 8.6 kPa provided the best balance between sensitivity and specificity for ruling in at least moderate liver fibrosis (F 2)<sup>43</sup> (Table 1). VCTE performs best at ruling out advanced fibrosis with a consistently high negative predictive value between studies.<sup>38</sup> In addition to fibrosis, a number of other factors may elevate the LSM including right heart failure, inexperienced operator, hepatic inflammation with high ALT, recent food ingestion, cholestasis, and active alcohol use.<sup>46</sup> These factors should be considered when interpreting VCTE results, particularly in the setting of an unexpectedly high LSM.

Other ultrasound-based technologies include supersonic shear imaging (SSI)<sup>47</sup> and acoustic radiation force impulse (ARFI)<sup>48</sup>, which are both integrated into a standard ultrasound unit. For SSI, focused ultrasonic beams create the shear wave and a very high frame rate ultrasound sequence captures the real time propagation of the shear wave through the liver.<sup>49</sup> The shear wave speed is measured by a Doppler-like acquisition over a 1 cm region of interest that is selected by the operator and the device automatically calculates the mean liver stiffness over the region of interest. A fibrotic liver will be stiffer and appear red. The screen displays the mean, minimum, maximum and standard deviation of the measurement, as well as the diameter of the circle. For ARFI, an acoustic 'push' generates the shear wave over the selected region of interest. The resultant shear wave is tracked as it propagates through the liver tissue by the ultrasound receiver, which estimates the shear-wave speed in meters per second, which is proportional to the square root of the shear moduli (measured in kPa). The operator determines if the images are adequate after evaluating for motion artifact or other issues with image acquisition. A study found that SSI, ARFI, and VCTE all had similarly high performance for the evaluation of advanced fibrosis compared to liver biopsy (AUROC for F 3 fibrosis stage: 0.89, 0.84, 0.86, respectively).<sup>50</sup> Obesity contributed to study failure or unreliable results for SSI, ARFI, and VCTE, though this study was conducted before the VCTE XL probe was available.<sup>50</sup>

Magnetic Resonance Elastography (MRE) is a reproducible method to non-invasively measure hepatic fibrosis by imaging approximately 5% of the liver.<sup>51</sup> MRE uses specialized hardware and software added to a conventional MRI. A circular device placed anterior to the



liver is attached to the patient and connected to an active acoustic driver located outside of the MRI room. As the patient perform breath holds, the device generates shear waves at 60 Hz which propagate through the liver. Images are interpreted using a commercial software to generate multicolor maps of liver stiffness over specified regions of interest. Unlikely ultrasound-based elastography, MRE can discriminate between different hepatic fibrosis stages.<sup>34, 38, 52</sup> Additionally, MRE consistently is the most accurate elastography method (AUROC 0.93) at a cut off of 3.6 kPa (Table 1).<sup>34, 38</sup> MRE failure rate is low, though increased hepatic iron, inflammation, or right heart failure may result in failure or false positive results.<sup>53, 54</sup> MRE may also not be possible in patients with implanted metallic devices or who exceed the weight limitations of the MRI scanner. In head to head comparative studies in patients with biopsy-proven NAFLD with contemporaneous MRE and VCTE, MRE is consistently superior than VCTE in differentiating each stage of fibrosis.<sup>38, 39, 55</sup> A comparison of the clinical use and advantages and limitations of various NITs for NAFLD (including NASH and hepatic fibrosis) is presented in Table 2.

**Novel biomarkers:** The human intestinal microbiota may contribute to the progression of simple steatosis to NASH and fibrosis though influencing hepatic lipid and bile acid metabolism and contributing to endogenous alcohol consumption.<sup>56</sup> Studies of the microbiome composition may be useful as a non-invasive method to distinguish between various NAFLD phenotypes. In a small cohort of patients with NAFLD at various stages, disease severity was associated with distinct microbiota signatures with an increase in *Bacteroides* in those with NASH compared to non-NASH and an increase in *Ruminococcus* in those with stage 2–4 fibrosis compare to those without significant fibrosis.<sup>57</sup> Though another study, which evaluated bacterial DNA from blood-based samples, found lower *Ruminococcaceae* in patients with hepatic fibrosis.<sup>58</sup> In a cohort of biopsy-defined NAFLD, a gut microbiome-derived metagenomic signature was highly accurate in detecting the presence of advanced fibrosis (AUROC 0.936).<sup>59</sup> Using an integrative multi-omics approach in a multi-center cohort of well-phenotyped, non-obese women without diabetes, Hoyles et al identified cross-talk between the gut microbiome and host gene expression and metabolism.<sup>60</sup> Individuals with hepatic steatosis had low microbial gene richness and a distinct molecular signature that robustly distinguished individuals with hepatic steatosis with an AUROC of 0.87.<sup>60</sup> They noted that aromatic amino acids are associated with NAFLD, and these findings were also replicated in a twin-family based study, comparing those with advanced fibrosis based upon MRE versus those with those with no or mild/moderate fibrosis.<sup>61</sup> Utilizing a family-based study including probands with NAFLD cirrhosis and referrants and their respective first-degree relatives, a gut microbiome signature for NAFLD cirrhosis was developed using 27 bacterial features and it was able to detect advanced fibrosis among first-degree relatives of these probands.<sup>62</sup> These data suggest that gut microbiome derived signature may be used as a diagnostic test for advanced fibrosis or cirrhosis in patients with NAFLD. Additional human studies are needed to determine if microbiobial signatures are generalizable across different populations and remain after adjusting for confounding factors.

Advances in ‘omics’ research over the last decade has led to important insights into the pathophysiology of NAFLD. Biomarkers derived from metabolomics may be useful in



differentiating NAFLD phenotypes. One small study found that a machine learning-derived model which included lipid, glycan, and hormonal biomarkers was highly accurate at distinguishing between NASH, simple steatosis and healthy phenotypes.<sup>24</sup> Additional studies are needed to identify additional biomarkers and for validation in other cohorts.

### **Biomarkers of disease activity and clinical outcomes**

In addition to diagnosis and risk stratification, it is critically important to identify biomarkers that accurately measure changes in NASH and hepatic fibrosis in order to monitor disease progression and response to therapy. As many of the clinically important outcomes in liver disease, such as progression to cirrhosis, decompensation, and death, thankfully, take many years to develop, surrogate markers, which are predictive of future events are also needed.

**Blood-based biomarkers of disease activity**—The simplest biomarker of treatment response is ALT, which has been utilized as a surrogate marker of liver damage in several studies. In the treatment of nonalcoholic fatty liver disease in children (TONIC) study, each unit decrease in ALT was associated with a 30% increased odds of histologic improvement<sup>63</sup> and mean change in ALT is considered a proxy for histologic improvement in NASH.<sup>64</sup>

Few studies have evaluated the ability of blood-based fibrosis models to detect changes in histologic fibrosis. In a study of 261 patients with biopsy-confirmed NASH at baseline and 1 year after lifestyle intervention, changes in NFS were independently associated with fibrosis improvement or progression.<sup>65</sup> Though change in platelet count, which is a component of the aspartate-aminotransferase-to-platelet ratio index (APRI) and FIB4 index, also associated with fibrosis improvement or progression, no associations between changes in APRI or FIB4 and fibrosis change were observed.<sup>65</sup> However, in a secondary analysis of the Phase 2B Farnesoid X Receptor Ligand Obeticholic Acid in Non-alcoholic Steatohepatitis Treatment (FLINT) trial, patients with histologic fibrosis improvement at week 24 demonstrated reductions in APRI, FIB4, and NFS; however, only reductions in APRI and FIB4 significantly correlated with at least a 1 stage improvement in fibrosis at week 72.<sup>66</sup> In a phase 2 clinical trial, improvement in the Enhanced Liver Fibrosis (ELF) test associated with fibrosis regression<sup>67</sup>; though in another secondary analysis, the ELF test did not associate with progression to cirrhosis.<sup>68</sup> A new model for predicting fibrosis improvement consisting of glycated hemoglobin, platelets, and ALT shows promise with an AUROC of 0.96 for fibrosis improvement, though external validation is needed before this model can be incorporated into practice.<sup>65</sup>

**Imaging-based biomarkers of disease activity**—The usefulness of ultrasound-based elastography modalities to monitor disease activity is not known as there may be substantial variability in measurements unrelated to regression or progression of fibrosis.<sup>69</sup> Longitudinal studies with serial VCTE examinations and histologic evaluations are limited so more data are needed. There is some evidence in chronic hepatitis B that longitudinal changes in VCTE-liver stiffness may relate to histologic progression of disease, but additional studies are needed.<sup>70</sup>

Magnetic resonance imaging-estimated protein density fat fraction (MRI-PDFF) is a quantitative biomarker of hepatic steatosis. High MRI-PDFF is also associated with early

fibrosis progression and less improvement in NASH.<sup>71</sup> Prior studies have demonstrated that MRI-PDFF correlates with histologic steatosis grade in both cross-sectional<sup>72</sup> and longitudinal studies.<sup>73, 74</sup> Improvement in MRI-PDFF is used to assess longitudinal changes in hepatic steatosis in clinical studies of NAFLD<sup>67, 75–77</sup> at early stages of development.<sup>78</sup> A reduction of MRI-PDFF by 30% is associated with histologic improvement in NAFLD Activity Score.<sup>79</sup> These data were subsequently validated in the Selonsertib Phase 2b trial as well as in a subset of the FLINT Trial<sup>80</sup>, and now confirmed in a recent trial using Resmetirom versus placebo for the treatment of NASH.<sup>67</sup>

MRE has also been studied as a potential imaging modality to monitor disease activity. The majority of studies which have evaluated the performance of MRE compared to liver histology are cross-sectional and limited longitudinal data exist. In a secondary-analysis of patients enrolled in a phase 2 study of selonsertib, increases or decreases in MRE-liver stiffness significantly associated with histologic fibrosis progression or regression, respectively; though the sample size was small and the AUROCs were modest.<sup>67</sup> Recently, a small, well-characterized cohort of patients with NAFLD and paired liver histology and MRE measurements demonstrated that a 15% increase in MRE was associated with histologic fibrosis progression, even after accounting for baseline BMI.<sup>81</sup> However, a worsening of liver stiffness on MRE by 15% was associated with higher odds of histologic progression of fibrosis.<sup>81</sup> Additional studies are needed to assess the association between changes in MRE liver stiffness and clinically relevant liver outcomes – including progression to cirrhosis, decompensation and liver-related death.

**Non-invasive biomarkers and clinical outcomes**—In a retrospective cohort study, elevated APRI and FIB4 were associated with liver-related outcomes over up to 8 years of follow-up.<sup>82</sup> In a separate study, an ELF score  $> 9.49$  had a higher sensitivity and specificity for predicting liver-related outcomes over 6 years compared to liver biopsy.<sup>83</sup> Change in liver stiffness may be an important biomarker of liver related events, though specific studies in NAFLD are needed. In one study, LSM derived from VCTE had a similarly high discriminative ability to predict liver-related mortality compared to FIB4.<sup>84</sup> Additionally, in a longitudinal cohort, each stage increase in VCTE-defined fibrosis stage was associated with a lower overall survival.<sup>84</sup> In a meta-analysis, high liver stiffness was associated with a significant risk for hepatic decompensation (relative risk 1.07; 95% CI 1.03–1.11), liver cancer (RR 1.11; 95% CI, 1.05–1.18), and death (RR, 1.22; 95% CI, 1.05–1.43).<sup>85</sup> In a study of patients with primary biliary cirrhosis, chronic cholestatic liver disease, a 2.1 kPa per year increase in LSM derived from VCTE was associated with an 8-fold increased risk of liver decompensation, liver transplantations, and deaths.<sup>86</sup> Baseline liver stiffness measure by SSI correlated with hepatic venous pressures gradient.<sup>87</sup> Changes in liver stiffness, measured by SSI, were strongly correlated with changes in the hepatic venous pressure gradient measurements, a measurement of portal hypertension, indicating a possible role for SSI to predict clinically significant portal hypertension and response to therapy.<sup>88</sup>

## Conclusions:

Accurate methods to diagnosis and monitor NASH and hepatic fibrosis are critically important for ongoing progress towards preventing liver-related morbidity and mortality.

Though there has been significant progress in the noninvasive diagnosis of hepatic fibrosis, advances in the noninvasive diagnosis of NASH lag behind. Large, diverse, cohorts of participants who are well-characterized for NAFLD, NASH, and fibrosis are needed for biomarker discovery. Genomics, metabolomics, and other “omics” technologies may be useful in improving our understanding of disease mechanisms and identifying novel biomarkers of disease activity. However, deep phenotyping and genotyping of large cohorts of participants are needed for both discovery and validation of potential biomarkers.

Despite advances, there still remains many unanswered questions in the non-invasive diagnosis of fibrosis, including a lack of clarity as to the optimal cutoff values for different imaging modalities and in different patient populations. NITs may be useful for risk stratification, which can lower costs and specialist referrals and reduce the number of patients subject to the risks of liver biopsy. However, best practices for using NITs to risk stratify or select patients for treatment are needed as there currently is a lot of practice variability. As new therapies are evaluated for NASH and fibrosis, we need to understand how changes in blood- and imaging-based biomarkers may relate to disease activity. Currently we rely on repeat liver biopsy to monitor disease activity, but this method is costly, invasive, and, ultimately, hindering medical progress. We need to invest in creating diverse cohorts of participants whom have undergone multiple non-invasive measures of fibrosis and who are monitored for the development of important clinical outcomes. Such cohorts will add in the development and validation of novel biomarkers that predict clinically relevant outcomes which are urgently needed as the prevalence of hepatic fibrosis secondary to NASH continues to rise

## Grant Support/Acknowledgements

Dr. Long is supported in part by the National Institute of Diabetes and Digestive and Kidney Diseases K23 DK113252, Gilead Sciences, the Doris Duke Foundation, the Boston University School of Medicine Department of Medicine Career Investment Award and the Boston University Clinical Translational Science Institute UL1 TR001430. Dr. Loomba is supported in part by NIEHS (5P42ES010337), NCATS (5UL1TR001442), NIDDK (R01DK106419, P30DK120515 R01DK121378), and DOD PRCRP (W81XWH-18-2-0026). The funding sources did not have any role in the writing of this manuscript.

### Conflicts of Interest:

MTL receives research grant support from Echosens Corporation and Gilead Sciences and serves as a consultant or advisory board member for Iterative Scopes and Ionis Pharmaceuticals. RL serves as a consultant or advisory board member for Arrowhead Pharmaceuticals, AstraZeneca, Bird Rock Bio, Boehringer Ingelheim, Bristol-Myer Squibb, Celgene, Cirus, CohBar, Conatus, Eli Lilly, Galmed, Gemphire, Gilead, Glympse bio, GNI, GRI Bio, Intercept, Ionis, Janssen Inc., Merck, Metacrine, Inc., NGM Biopharmaceuticals, Novartis, Novo Nordisk, Pfizer, Prometheus, Sanofi, Siemens, and Viking Therapeutics. In addition, his institution has received grant support from Allergan, Boehringer-Ingelheim, Bristol-Myers Squibb, Cirus, Eli Lilly and Company, Galectin Therapeutics, Galmed Pharmaceuticals, GE, Genfit, Gilead, Intercept, Grail, Janssen, Madrigal Pharmaceuticals, Merck, NGM Biopharmaceuticals, NuSirt, Pfizer, pH Pharma, Prometheus, and Siemens. He is also co-founder of Liponex, Inc.

## Abbreviations:

<b>NAFLD</b>	Non-alcoholic fatty liver disease
<b>NASH</b>	non-alcoholic steatohepatitis
<b>NITs</b>	noninvasive tests

<b>CT</b>	computed tomography
<b>US</b>	ultrasound
<b>MRI</b>	magnetic imaging resonance
<b>ALT</b>	alanine aminotransferase
<b>CK18</b>	cytokeratin 18
<b>PAI-1</b>	plasminogen activator inhibitor
<b>OR</b>	odds ratio
<b>CI</b>	confidence interval
<b>AUROC</b>	area under the receiver operator characteristic
<b>oxNASH</b>	13-hydroxy octadecadenoic acid to linoleic acid
<b>FGF21</b>	fibroblast growth factor 21
<b>NFS</b>	NAFLD fibrosis score
<b>FIB4</b>	fibrosis 4 index
<b>BMI</b>	body mass index
<b>AST</b>	aspartate aminotransferase
<b>VCTE</b>	vibration-controlled transient elastography
<b>IQR/M</b>	interquartile range/median
<b>LSM</b>	liver stiffness measurement
<b>CAP</b>	controlled attenuation paramete
<b>SSI</b>	supersonic shear imaging
<b>ARFI</b>	acoustic radiation force imaging
<b>MRE</b>	magnetic resonance elastography
<b>MRI-PDF</b>	magnetic resonance imaging – proton density fat fraction
<b>FDA</b>	food and drug administration
<b>FLINT</b>	Farnesoid X Receptor Ligand Obeticholic Acid in Non-alcoholic Steatohepatitis Treatment
<b>APRI</b>	aspartate-to-platelet ratio index
<b>ELF</b>	the Enhanced Liver Fibrosis
<b>TONIC</b>	treatment of nonalcoholic fatty liver disease in children

## References:

1. Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L and Wymer M. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. *Hepatology*. 2016;64:73–84. [PubMed: 26707365]
2. Loomba R and Sanyal AJ. The global NAFLD epidemic. *Nat Rev Gastroenterol Hepatol*. 2013;10:686–90. [PubMed: 24042449]
3. Chalasani N, Younossi Z, Lavine JE, Charlton M, Cusi K, Rinella M, Harrison SA, Brunt EM and Sanyal AJ. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. *Hepatology*. 2018;67:328–357. [PubMed: 28714183]
4. Singh S, Allen AM, Wang Z, Prokop LJ, Murad MH and Loomba R. Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies. *Clin Gastroenterol Hepatol*. 2015;13:643–54 e1–9; quiz e39–40. [PubMed: 24768810]
5. Angulo P, Kleiner DE, Dam-Larsen S, Adams LA, Bjornsson ES, Charatcharoenwittaya P, Mills PR, Keach JC, Lafferty HD, Stahler A, Haflidadottir S and Bendtsen F. Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease. *Gastroenterology*. 2015;149:389–97.e10. [PubMed: 25935633]
6. Allen AM, Therneau TM, Larson JJ, Coward A, Somers VK and Kamath PS. Nonalcoholic fatty liver disease incidence and impact on metabolic burden and death: A 20 year-community study. *Hepatology*. 2018;67:1726–1736. [PubMed: 28941364]
7. Allen AM, Hicks SB, Mara KC, Larson JJ and Therneau TM. The risk of incident extrahepatic cancers is higher in non-alcoholic fatty liver disease than obesity - A longitudinal cohort study. *J Hepatol*. 2019;71:1229–1236. [PubMed: 31470068]
8. Ma J, Hwang SJ, Pedley A, Massaro JM, Hoffmann U, Chung RT, Benjamin EJ, Levy D, Fox CS and Long MT. Bi-directional analysis between fatty liver and cardiovascular disease risk factors. *J Hepatol*. 2017;66:390–397. [PubMed: 27729222]
9. Dulai PS, Singh S, Patel J, Soni M, Prokop LJ, Younossi Z, Sebastiani G, Ekstedt M, Hagstrom H, Nasr P, Stal P, Wong VW, Kechagias S, Hultcrantz R and Loomba R. Increased risk of mortality by fibrosis stage in non-alcoholic fatty liver disease: Systematic Review and Meta-analysis. *Hepatology*. 2017.
10. Cheung A, Neuschwander-Tetri BA, Kleiner DE, Schabel E, Rinella M, Harrison S, Ratziu V, Sanyal AJ, Loomba R, Jeannin Megnien S, Torstenson R and Miller V. Defining Improvement in Nonalcoholic Steatohepatitis for Treatment Trial Endpoints: Recommendations From the Liver Forum. *Hepatology*. 2019;70:1841–1855. [PubMed: 31034092]
11. Rowe IA and Parker R. Liver biopsy for the selection of patients with nonalcoholic steatohepatitis for clinical trials. *Gastroenterology*. 2015;148:262.
12. Bedossa P, Dargere D and Paradis V. Sampling variability of liver fibrosis in chronic hepatitis C. *Hepatology*. 2003;38:1449–57. [PubMed: 14647056]
13. Verhaegh P, Bavalia R, Winkens B, Masclee A, Jonkers D and Koek G. Noninvasive Tests Do Not Accurately Differentiate Nonalcoholic Steatohepatitis From Simple Steatosis: A Systematic Review and Meta-analysis. *Clin Gastroenterol Hepatol*. 2018;16:837–861. [PubMed: 28838784]
14. Verma S, Jensen D, Hart J and Mohanty SR. Predictive value of ALT levels for non-alcoholic steatohepatitis (NASH) and advanced fibrosis in non-alcoholic fatty liver disease (NAFLD). *Liver Int*. 2013;33:1398–405. [PubMed: 23763360]
15. Wong VW, Wong GL, Tsang SW, Hui AY, Chan AW, Choi PC, Chim AM, Chu S, Chan FK, Sung JJ and Chan HL. Metabolic and histological features of non-alcoholic fatty liver disease patients with different serum alanine aminotransferase levels. *Aliment Pharmacol Ther*. 2009;29:387–96. [PubMed: 19035982]
16. Kwok R, Tse YK, Wong GL, Ha Y, Lee AU, Ngu MC, Chan HL and Wong VW. Systematic review with meta-analysis: non-invasive assessment of non-alcoholic fatty liver disease--the role of transient elastography and plasma cytokeratin-18 fragments. *Aliment Pharmacol Ther*. 2014;39:254–69. [PubMed: 24308774]

17. Ajmera V, Perito ER, Bass NM, Terrault NA, Yates KP, Gill R, Loomba R, Diehl AM, Aouizerat BE and Network NCR. Novel plasma biomarkers associated with liver disease severity in adults with nonalcoholic fatty liver disease. *Hepatology*. 2017;65:65–77. [PubMed: 27532276]
18. Kaikita K, Fogo AB, Ma L, Schoenhard JA, Brown NJ and Vaughan DE. Plasminogen activator inhibitor-1 deficiency prevents hypertension and vascular fibrosis in response to long-term nitric oxide synthase inhibition. *Circulation*. 2001;104:839–44. [PubMed: 11502712]
19. Targher G, Bertolini L, Scala L, Zenari L, Lippi G, Franchini M and Arcaro G. Plasma PAI-1 levels are increased in patients with nonalcoholic steatohepatitis. *Diabetes Care*. 2007;30:e31–2. [PubMed: 17468361]
20. Feldstein AE, Lopez R, Tamimi TA, Yerian L, Chung YM, Berk M, Zhang R, McIntyre TM and Hazen SL. Mass spectrometric profiling of oxidized lipid products in human nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. *J Lipid Res*. 2010;51:3046–54. [PubMed: 20631297]
21. Alkhoury N, Dixon LJ and Feldstein AE. Lipotoxicity in nonalcoholic fatty liver disease: not all lipids are created equal. *Expert Rev Gastroenterol Hepatol*. 2009;3:445–51. [PubMed: 19673631]
22. Loomba R, Quehenberger O, Armando A and Dennis EA. Polyunsaturated fatty acid metabolites as novel lipidomic biomarkers for noninvasive diagnosis of nonalcoholic steatohepatitis. *J Lipid Res*. 2015;56:185–92. [PubMed: 25404585]
23. Puri P, Baillie RA, Wiest MM, Mirshahi F, Choudhury J, Cheung O, Sargeant C, Contos MJ and Sanyal AJ. A lipidomic analysis of nonalcoholic fatty liver disease. *Hepatology*. 2007;46:1081–90. [PubMed: 17654743]
24. Perakakis N, Polyzos SA, Yazdani A, Sala-Vila A, Kountouras J, Anastasilakis AD and Mantzoros CS. Non-invasive diagnosis of non-alcoholic steatohepatitis and fibrosis with the use of omics and supervised learning: A proof of concept study. *Metabolism*. 2019;101:154005.
25. Tucker B, Li H, Long X, Rye KA and Ong KL. Fibroblast growth factor 21 in non-alcoholic fatty liver disease. *Metabolism*. 2019;101:153994.
26. Sanyal A, Charles ED, Neuschwander-Tetri BA, Loomba R, Harrison SA, Abdelmalek MF, Lawitz EJ, Halegoua-DeMarzio D, Kundu S, Noviello S, Luo Y and Christian R. Pegbelfermin (BMS-986036), a PEGylated fibroblast growth factor 21 analogue, in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 2a trial. *Lancet*. 2019;392:2705–2717. [PubMed: 30554783]
27. Patel NS, Hooker J, Gonzalez M, Bhatt A, Nguyen P, Ramirez K, Richards L, Rizo E, Hernandez C, Kisseleva T, Schnabl B, Brenner D, Sirlin CB and Loomba R. Weight Loss Decreases Magnetic Resonance Elastography Estimated Liver Stiffness in Nonalcoholic Fatty Liver Disease. *Clin Gastroenterol Hepatol*. 2017;15:463–464. [PubMed: 27712981]
28. Shen J, Chan HL, Wong GL, Choi PC, Chan AW, Chan HY, Chim AM, Yeung DK, Chan FK, Woo J, Yu J, Chu WC and Wong VW. Non-invasive diagnosis of non-alcoholic steatohepatitis by combined serum biomarkers. *J Hepatol*. 2012;56:1363–70. [PubMed: 22314419]
29. Tong X, Muchnik M, Chen Z, Patel M, Wu N, Joshi S, Rui L, Lazar MA and Yin L. Transcriptional repressor E4-binding protein 4 (E4BP4) regulates metabolic hormone fibroblast growth factor 21 (FGF21) during circadian cycles and feeding. *J Biol Chem*. 2010;285:36401–9. [PubMed: 20851878]
30. Yu H, Xia F, Lam KS, Wang Y, Bao Y, Zhang J, Gu Y, Zhou P, Lu J, Jia W and Xu A. Circadian rhythm of circulating fibroblast growth factor 21 is related to diurnal changes in fatty acids in humans. *Clin Chem*. 2011;57:691–700. [PubMed: 21325103]
31. Wong VW, Adams LA, de Ledinghen V, Wong GL and Sookoian S. Noninvasive biomarkers in NAFLD and NASH - current progress and future promise. *Nat Rev Gastroenterol Hepatol*. 2018;15:461–478. [PubMed: 29844588]
32. Angulo P, Hui JM, Marchesini G, Bugianesi E, George J, Farrell GC, Enders F, Saksena S, Burt AD, Bida JP, Lindor K, Sanderson SO, Lenzi M, Adams LA, Kench J, Therneau TM and Day CP. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. *Hepatology*. 2007;45:846–54. [PubMed: 17393509]
33. Sterling RK, Lissen E, Clumeck N, Sola R, Correa MC, Montaner J, M SS, Torriani FJ, Dieterich DT, Thomas DL, Messinger D and Nelson M. Development of a simple noninvasive index to



- predict significant fibrosis in patients with HIV/HCV coinfection. *Hepatology*. 2006;43:1317–25. [PubMed: 16729309]
34. Xiao G, Zhu S, Xiao X, Yan L, Yang J and Wu G. Comparison of laboratory tests, ultrasound, or magnetic resonance elastography to detect fibrosis in patients with nonalcoholic fatty liver disease: A meta-analysis. *Hepatology*. 2017;66:1486–1501. [PubMed: 28586172]
  35. Vilar-Gomez E and Chalasani N. Non-invasive assessment of non-alcoholic fatty liver disease: Clinical prediction rules and blood-based biomarkers. *J Hepatol*. 2018;68:305–315. [PubMed: 29154965]
  36. Younossi ZM and Henry L. Are Noninvasive Scoring Systems for Persons With Chronic Liver Disease Ready for Prime Time? *Gastroenterology*. 2020;158:40–42. [PubMed: 31743732]
  37. McPherson S, Hardy T, Dufour JF, Petta S, Romero-Gomez M, Allison M, Oliveira CP, Francque S, Van Gaal L, Schattenberg JM, Tiniakos D, Burt A, Bugianesi E, Ratziu V, Day CP and Anstee QM. Age as a Confounding Factor for the Accurate Non-Invasive Diagnosis of Advanced NAFLD Fibrosis. *Am J Gastroenterol*. 2017;112:740–751. [PubMed: 27725647]
  38. Hsu C, Caussy C, Imajo K, Chen J, Singh S, Kaulback K, Le MD, Hooker J, Tu X, Bettencourt R, Yin M, Sirlin CB, Ehman RL, Nakajima A and Loomba R. Magnetic Resonance vs Transient Elastography Analysis of Patients With Nonalcoholic Fatty Liver Disease: A Systematic Review and Pooled Analysis of Individual Participants. *Clin Gastroenterol Hepatol*. 2019;17:630–637 e8. [PubMed: 29908362]
  39. Park CC, Nguyen P, Hernandez C, Bettencourt R, Ramirez K, Fortney L, Hooker J, Sy E, Savides MT, Alquiraish MH, Valasek MA, Rizo E, Richards L, Brenner D, Sirlin CB and Loomba R. Magnetic Resonance Elastography vs Transient Elastography in Detection of Fibrosis and Noninvasive Measurement of Steatosis in Patients With Biopsy-Proven Nonalcoholic Fatty Liver Disease. *Gastroenterology*. 2017;152:598–607.e2. [PubMed: 27911262]
  40. Newsome PN, Sasso M, Deeks JJ, Paredes A, Boursier J, Chan WK, Yilmaz Y, Czernichow S, Zheng MH, Wong VW, Allison M, Tsochatzis E, Anstee QM, Sheridan DA, Eddowes PJ, Guha IN, Cobbold JF, Paradis V, Bedossa P, Miette V, Fournier-Poizat C, Sandrin L and Harrison SA. FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study. *Lancet Gastroenterol Hepatol*. 2020;5:362–373.
  41. Boursier J, Zarski JP, de Ledinghen V, Rousselet MC, Sturm N, Lebaill B, Fouchard-Hubert I, Gallois Y, Oberti F, Bertrais S, Cales P and Multicentric Group from AHCEPFS. Determination of reliability criteria for liver stiffness evaluation by transient elastography. *Hepatology*. 2013;57:1182–91. [PubMed: 22899556]
  42. Vuppalanchi R, Siddiqui MS, Van Natta ML, Hallinan E, Brandman D, Kowdley K, Neuschwander-Tetri BA, Loomba R, Dasarathy S, Abdelmalek M, Doo E, Tonascia JA, Kleiner DE, Sanyal AJ and Chalasani N. Performance characteristics of vibration-controlled transient elastography for evaluation of nonalcoholic fatty liver disease. *Hepatology*. 2018;67:134–144. [PubMed: 28859228]
  43. Siddiqui MS, Vuppalanchi R, Van Natta ML, Hallinan E, Kowdley KV, Abdelmalek M, Neuschwander-Tetri BA, Loomba R, Dasarathy S, Brandman D, Doo E, Tonascia JA, Kleiner DE, Chalasani N and Sanyal AJ. Vibration-Controlled Transient Elastography to Assess Fibrosis and Steatosis in Patients With Nonalcoholic Fatty Liver Disease. *Clin Gastroenterol Hepatol*. 2019;17:156–163.e2. [PubMed: 29705261]
  44. Tapper EB and Loomba R. Noninvasive imaging biomarker assessment of liver fibrosis by elastography in NAFLD. *Nat Rev Gastroenterol Hepatol*. 2018;15:274–282. [PubMed: 29463906]
  45. Wong VW, Vergniol J, Wong GL, Foucher J, Chan AW, Chermak F, Choi PC, Merrouche W, Chu SH, Pesque S, Chan HL and de Ledinghen V. Liver stiffness measurement using XL probe in patients with nonalcoholic fatty liver disease. *Am J Gastroenterol*. 2012;107:1862–71. [PubMed: 23032979]
  46. Tapper EB, Castera L and Afdhal NH. FibroScan (vibration-controlled transient elastography): where does it stand in the United States practice. *Clin Gastroenterol Hepatol*. 2015;13:27–36. [PubMed: 24909907]

47. Ferraioli G, Tinelli C, Dal Bello B, Zicchetti M, Filice G, Filice C and Liver Fibrosis Study G. Accuracy of real-time shear wave elastography for assessing liver fibrosis in chronic hepatitis C: a pilot study. *Hepatology*. 2012;56:2125–33. [PubMed: 22767302]
48. Fierbinteanu-Braticevici C, Andronescu D, Usvat R, Cretoiu D, Baicus C and Marinoschi G. Acoustic radiation force imaging sonoelastography for noninvasive staging of liver fibrosis. *World J Gastroenterol*. 2009;15:5525–32. [PubMed: 19938190]
49. Sporea I, Mare R, Lupusoru R, Sima A, Sirlu R, Popescu A and Timar R. Liver Stiffness Evaluation by Transient Elastography in Type 2 Diabetes Mellitus Patients with Ultrasound-proven Steatosis. *J Gastrointest Liver Dis*. 2016;25:167–74. [PubMed: 27308647]
50. Cassinotto C, Boursier J, de Ledinghen V, Lebigot J, Lapuyade B, Cales P, Hiriart JB, Michalak S, Bail BL, Cartier V, Mouries A, Oberti F, Fouchard-Hubert I, Vergniol J and Aube C. Liver stiffness in nonalcoholic fatty liver disease: A comparison of supersonic shear imaging, FibroScan, and ARFI with liver biopsy. *Hepatology*. 2016;63:1817–27. [PubMed: 26659452]
51. Venkatesh SK, Wang G, Teo LL and Ang BW. Magnetic resonance elastography of liver in healthy Asians: normal liver stiffness quantification and reproducibility assessment. *J Magn Reson Imaging*. 2014;39:1–8. [PubMed: 24123300]
52. Singh S, Venkatesh SK, Loomba R, Wang Z, Sirlin C, Chen J, Yin M, Miller FH, Low RN, Hassanein T, Godfrey EM, Asbach P, Murad MH, Lomas DJ, Talwalkar JA and Ehman RL. Magnetic resonance elastography for staging liver fibrosis in non-alcoholic fatty liver disease: a diagnostic accuracy systematic review and individual participant data pooled analysis. *Eur Radiol*. 2016;26:1431–40. [PubMed: 26314479]
53. Chen J, Yin M, Talwalkar JA, Oudry J, Glaser KJ, Smyrk TC, Miette V, Sandrin L and Ehman RL. Diagnostic Performance of MR Elastography and Vibration-controlled Transient Elastography in the Detection of Hepatic Fibrosis in Patients with Severe to Morbid Obesity. *Radiology*. 2017;283:418–428. [PubMed: 27861111]
54. Wagner M, Corcuera-Solano I, Lo G, Esses S, Liao J, Besa C, Chen N, Abraham G, Fung M, Babb JS, Ehman RL and Taouli B. Technical Failure of MR Elastography Examinations of the Liver: Experience from a Large Single-Center Study. *Radiology*. 2017;284:401–412. [PubMed: 28045604]
55. Imajo K, Kessoku T, Honda Y, Tomeno W, Ogawa Y, Mawatari H, Fujita K, Yoneda M, Taguri M, Hyogo H, Sumida Y, Ono M, Eguchi Y, Inoue T, Yamanaka T, Wada K, Saito S and Nakajima A. Magnetic Resonance Imaging More Accurately Classifies Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease Than Transient Elastography. *Gastroenterology*. 2016;150:626–637.e7. [PubMed: 26677985]
56. Anand G, Zarrinpar A and Loomba R. Targeting Dysbiosis for the Treatment of Liver Disease. *Semin Liver Dis*. 2016;36:37–47. [PubMed: 26870931]
57. Boursier J, Mueller O, Barret M, Machado M, Fizanne L, Araujo-Perez F, Guy CD, Seed PC, Rawls JF, David LA, Hunault G, Oberti F, Cales P and Diehl AM. The severity of nonalcoholic fatty liver disease is associated with gut dysbiosis and shift in the metabolic function of the gut microbiota. *Hepatology*. 2016;63:764–75. [PubMed: 26600078]
58. Lelouvier B, Servant F, Paisse S, Brunet AC, Benyahya S, Serino M, Valle C, Ortiz MR, Puig J, Courtney M, Federici M, Fernandez-Real JM, Burcelin R and Amar J. Changes in blood microbiota profiles associated with liver fibrosis in obese patients: A pilot analysis. *Hepatology*. 2016;64:2015–2027. [PubMed: 27639192]
59. Loomba R, Seguritan V, Li W, Long T, Klitgord N, Bhatt A, Dulai PS, Caussy C, Bettencourt R, Highlander SK, Jones MB, Sirlin CB, Schnabl B, Brinkac L, Schork N, Chen CH, Brenner DA, Biggs W, Yooseph S, Venter JC and Nelson KE. Gut Microbiome-Based Metagenomic Signature for Non-invasive Detection of Advanced Fibrosis in Human Nonalcoholic Fatty Liver Disease. *Cell Metab*. 2017;25:1054–1062 e5. [PubMed: 28467925]
60. Hoyles L, Fernandez-Real JM, Federici M, Serino M, Abbott J, Charpentier J, Heymes C, Luque JL, Anthony E, Barton RH, Chilloux J, Myridakis A, Martinez-Gili L, Moreno-Navarrete JM, Benhamed F, Azalbert V, Blasco-Baque V, Puig J, Xifra G, Ricart W, Tomlinson C, Woodbridge M, Cardellini M, Davato F, Cardolini I, Porzio O, Gentileschi P, Lopez F, Fougelle F, Butcher SA, Holmes E, Nicholson JK, Postic C, Burcelin R and Dumas ME. Molecular phenomics and

metagenomics of hepatic steatosis in non-diabetic obese women. *Nat Med.* 2018;24:1070–1080. [PubMed: 29942096]

61. Caussy C, Hsu C, Lo MT, Liu A, Bettencourt R, Ajmera VH, Bassirian S, Hooker J, Sy E, Richards L, Schork N, Schnabl B, Brenner DA, Sirlin CB, Chen CH, Loomba R and Genetics of NiTC. Novel link between gut-microbiome derived metabolite and shared gene-effects with hepatic steatosis and fibrosis in NAFLD. *Hepatology.* 2018.
62. Caussy C, Tripathi A, Humphrey G, Bassirian S, Singh S, Faulkner C, Bettencourt R, Rizo E, Richards L, Xu ZZ, Downes MR, Evans RM, Brenner DA, Sirlin CB, Knight R and Loomba R. A gut microbiome signature for cirrhosis due to nonalcoholic fatty liver disease. *Nat Commun.* 2019;10:1406. [PubMed: 30926798]
63. Vuppalanchi R, Jain AK, Deppe R, Yates K, Comerford M, Masuoka HC, Neuschwander-Tetri BA, Loomba R, Brunt EM, Kleiner DE, Molleston JP, Schwimmer JB, Lavine JE, Tonascia J and Chalasani N. Relationship between changes in serum levels of keratin 18 and changes in liver histology in children and adults with nonalcoholic fatty liver disease. *Clin Gastroenterol Hepatol.* 2014;12:2121–30.e1–2. [PubMed: 24846279]
64. Arsik I, Frediani JK, Frezza D, Chen W, Ayer T, Keskinocak P, Jin R, Konomi JV, Barlow SE, Xanthakos SA, Lavine JE and Vos MB. Alanine Aminotransferase as a Monitoring Biomarker in Children with Nonalcoholic Fatty Liver Disease: A Secondary Analysis Using TONIC Trial Data. *Children (Basel).* 2018;5.
65. Vilar-Gomez E, Calzadilla-Bertot L, Friedman SL, Gra-Oramas B, Gonzalez-Fabian L, Lazo-Del Vallin S, Diago M and Adams LA. Serum biomarkers can predict a change in liver fibrosis 1 year after lifestyle intervention for biopsy-proven NASH. *Liver Int.* 2017;37:1887–1896. [PubMed: 28544769]
66. Chalasani N, Abdelmalek MF, Loomba R, Kowdley KV, McCullough AJ, Dasarathy S, Neuschwander-Tetri BA, Terrault N, Ferguson B, Shringarpure R, Shapiro D and Sanyal AJ. Relationship between three commonly used non-invasive fibrosis biomarkers and improvement in fibrosis stage in patients with non-alcoholic steatohepatitis. *Liver Int.* 2019;39:924–932. [PubMed: 30253043]
67. Jayakumar S, Middleton MS, Lawitz EJ, Mantry PS, Caldwell SH, Arnold H, Mae Diehl A, Ghalib R, Elkhachab M, Abdelmalek MF, Kowdley KV, Stephen Djedjos C, Xu R, Han L, Mani Subramanian G, Myers RP, Goodman ZD, Afdhal NH, Charlton MR, Sirlin CB and Loomba R. Longitudinal correlations between MRE, MRI-PDFF, and liver histology in patients with non-alcoholic steatohepatitis: Analysis of data from a phase II trial of selonsertib. *J Hepatol.* 2019;70:133–141. [PubMed: 30291868]
68. Harrison SA AM, Diehl AM, Caldwell S, Shiffman ML, Ghalib R, Lawitz E, et al. Prospective validation of the Enhanced Liver Fibrosis (ELF) test for the prediction of disease progression in patients with nonalcoholic steatohepatitis (NASH) and advanced fibrosis. *Hepatology.* 2017;66:1120A–1121A.
69. Nascimbeni F, Lebray P, Fedchuk L, Oliveira CP, Alvares-da-Silva MR, Varault A, Ingiliz P, Ngo Y, de Torres M, Munteanu M, Poynard T, Ratziu V and Group LS. Significant variations in elastometry measurements made within short-term in patients with chronic liver diseases. *Clin Gastroenterol Hepatol.* 2015;13:763–71 e1–6. [PubMed: 25086193]
70. Wu SD, Liu LL, Cheng JL, Liu Y, Cheng LS, Wang SQ, Ma W, Chen LP, Tseng YJ, Wang JY, Shen XZ and Jiang W. Longitudinal monitoring of liver fibrosis status by transient elastography in chronic hepatitis B patients during long-term entecavir treatment. *Clin Exp Med.* 2018;18:433–443. [PubMed: 29696462]
71. Ajmera V, Park CC, Caussy C, Singh S, Hernandez C, Bettencourt R, Hooker J, Sy E, Behling C, Xu R, Middleton MS, Valasek MA, Faulkner C, Rizo E, Richards L, Sirlin CB and Loomba R. Magnetic Resonance Imaging Proton Density Fat Fraction Associates With Progression of Fibrosis in Patients With Nonalcoholic Fatty Liver Disease. *Gastroenterology.* 2018;155:307–310.e2. [PubMed: 29660324]
72. Heba ER, Desai A, Zand KA, Hamilton G, Wolfson T, Schlein AN, Gamst A, Loomba R, Sirlin CB and Middleton MS. Accuracy and the effect of possible subject-based confounders of magnitude-based MRI for estimating hepatic proton density fat fraction in adults, using MR spectroscopy as reference. *J Magn Reson Imaging.* 2016;43:398–406. [PubMed: 26201284]

73. Middleton MS, Heba ER, Hooker CA, Bashir MR, Fowler KJ, Sandrasegaran K, Brunt EM, Kleiner DE, Doo E, Van Natta ML, Lavine JE, Neuschwander-Tetri BA, Sanyal A, Loomba R, Sirlin CB and Network NCR. Agreement Between Magnetic Resonance Imaging Proton Density Fat Fraction Measurements and Pathologist-Assigned Steatosis Grades of Liver Biopsies From Adults With Nonalcoholic Steatohepatitis. *Gastroenterology*. 2017;153:753–761. [PubMed: 28624576]
74. Middleton MS, Van Natta ML, Heba ER, Alazraki A, Trout AT, Masand P, Brunt EM, Kleiner DE, Doo E, Tonascia J, Lavine JE, Shen W, Hamilton G, Schwimmer JB, Sirlin CB and Network NCR. Diagnostic accuracy of magnetic resonance imaging hepatic proton density fat fraction in pediatric nonalcoholic fatty liver disease. *Hepatology*. 2018;67:858–872. [PubMed: 29028128]
75. Loomba R, Sirlin CB, Ang B, Bettencourt R, Jain R, Salotti J, Soaft L, Hooker J, Kono Y, Bhatt A, Hernandez L, Nguyen P, Nouredin M, Haufe W, Hooker C, Yin M, Ehman R, Lin GY, Valasek MA, Brenner DA, Richards L and San Diego Integrated NRC. Ezetimibe for the treatment of nonalcoholic steatohepatitis: assessment by novel magnetic resonance imaging and magnetic resonance elastography in a randomized trial (MOZART trial). *Hepatology*. 2015;61:1239–50. [PubMed: 25482832]
76. Nouredin M, Lam J, Peterson MR, Middleton M, Hamilton G, Le TA, Bettencourt R, Changchien C, Brenner DA, Sirlin C and Loomba R. Utility of magnetic resonance imaging versus histology for quantifying changes in liver fat in nonalcoholic fatty liver disease trials. *Hepatology*. 2013;58:1930–40. [PubMed: 23696515]
77. Stanley TL, Fourman LT, Feldpausch MN, Purdy J, Zheng I, Pan CS, Aepfelbacher J, Buckless C, Tsao A, Kellogg A, Branch K, Lee H, Liu CY, Corey KE, Chung RT, Torriani M, Kleiner DE, Hadigan CM and Grinspoon SK. Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial. *Lancet HIV*. 2019.
78. Rinella ME, Tacke F, Sanyal AJ and Anstee QM. Report on the AASLD/EASL Joint Workshop on Clinical Trial Endpoints in NAFLD. *Hepatology*. 2019;70:1424–1436. [PubMed: 31287572]
79. Patel J, Bettencourt R, Cui J, Salotti J, Hooker J, Bhatt A, Hernandez C, Nguyen P, Aryafar H, Valasek M, Haufe W, Hooker C, Richards L, Sirlin CB and Loomba R. Association of noninvasive quantitative decline in liver fat content on MRI with histologic response in nonalcoholic steatohepatitis. *Therap Adv Gastroenterol*. 2016;9:692–701.
80. Harrison SA, Bashir MR, Guy CD, Zhou R, Moylan CA, Frias JP, Alkhoury N, Bansal MB, Baum S, Neuschwander-Tetri BA, Taub R and Moussa SE. Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. *Lancet*. 2019.
81. Ajmera VH, Liu A, Singh S, Yachoa G, Ramey M, Bhargava M, Zamani A, Lopez S, Mangla N, Bettencourt R, Rizo E, Valasek M, Behling C, Richards L, Sirlin C and Loomba R. Clinical utility of an increase in magnetic resonance elastography in predicting fibrosis progression in NAFLD. *Hepatology*. 2019.
82. Sebastiani G, Alshaalan R, Wong P, Rubino M, Salman A, Metrakos P, Deschenes M and Ghali P. Prognostic Value of Non-Invasive Fibrosis and Steatosis Tools, Hepatic Venous Pressure Gradient (HVPG) and Histology in Nonalcoholic Steatohepatitis. *PLoS One*. 2015;10:e0128774.
83. Parkes J, Roderick P, Harris S, Day C, Mutimer D, Collier J, Lombard M, Alexander G, Ramage J, Dusheiko G, Wheatley M, Gough C, Burt A and Rosenberg W. Enhanced liver fibrosis test can predict clinical outcomes in patients with chronic liver disease. *Gut*. 2010;59:1245–51. [PubMed: 20675693]
84. Boursier J, Vergniol J, Guillet A, Hiriart JB, Lannes A, Le Bail B, Michalak S, Chermak F, Bertrais S, Foucher J, Oberti F, Charbonnier M, Fouchard-Hubert I, Rousselet MC, Cales P and de Ledinghen V. Diagnostic accuracy and prognostic significance of blood fibrosis tests and liver stiffness measurement by FibroScan in non-alcoholic fatty liver disease. *J Hepatol*. 2016;65:570–8. [PubMed: 27151181]
85. Singh S, Fujii LL, Murad MH, Wang Z, Asrani SK, Ehman RL, Kamath PS and Talwalkar JA. Liver stiffness is associated with risk of decompensation, liver cancer, and death in patients with chronic liver diseases: a systematic review and meta-analysis. *Clin Gastroenterol Hepatol*. 2013;11:1573–84.e1–2; quiz e88–9. [PubMed: 23954643]

86. Corpechot C, Carrat F, Poujol-Robert A, Gaouar F, Wendum D, Chazouilleres O and Poupon R. Noninvasive elastography-based assessment of liver fibrosis progression and prognosis in primary biliary cirrhosis. *Hepatology*. 2012;56:198–208. [PubMed: 22271046]
87. rKim TY, Jeong WK, Sohn JH, Kim J, Kim MY and Kim Y. Evaluation of portal hypertension by real-time shear wave elastography in cirrhotic patients. *Liver Int*. 2015;35:2416–24 [PubMed: 25875718]
88. Choi SY, Jeong WK, Kim Y, Kim J, Kim TY and Sohn JH. Shear-wave elastography: a noninvasive tool for monitoring changing hepatic venous pressure gradients in patients with cirrhosis. *Radiology*. 2014;273:917–26. [PubMed: 25025464]

### Highlights

- Non-alcoholic fatty liver disease is the most common chronic liver disease
- Simple steatosis cannot be distinguished from steatohepatitis non-invasively
- Biomarkers for steatohepatitis are being developed but are not available yet for clinical use
- Hepatic fibrosis can be identified non-invasively using imaging or blood based biomarkers
- Magnetic Resonance Elastography provides the most accurate method for non-invasively diagnosing hepatic fibrosis



**Table 1:**

Vibration-Controlled Transient Elastography and Magnetic Resonance Elastography Based-Assessment of Liver Fibrosis.

Stage	Modality	AUROC	Threshold priority	LSM (kPa)	Sensitivity	Specificity	PPV	NPV
Early Disease detection								
F = 2	VCTE <sup>43</sup>	0.79	High Sensitivity	5.6	0.9	0.44	0.62	0.81
			Balanced	8.6	0.66	0.80	0.78	0.70
			High Specificity	11.9	0.40	0.90	0.80	0.59
	MRE <sup>38</sup>	0.92	Balanced	2.97	0.85	0.85	0.80	0.89
Cirrhosis detection								
F = 4	VCTE <sup>43</sup>	0.93	High Sensitivity	12.1	0.90	0.82	0.34	0.99
			Balanced	13.1	0.89	0.86	0.39	0.99
			High Specificity	14.9	0.69	0.90	0.41	0.59
	MRE <sup>38</sup>	0.94	Balanced	4.7	0.80	0.86	0.41	0.97

F, fibrosis stage; AUROC, area under the receiver operator characteristic; LSM, liver stiffness measurement; PPV, positive predictive value; NPV, negative predictive value; VCTE, vibration-controlled transient elastography; MRE, magnetic resonance elastography

**Table 2:** Advantages and Limitation of Common Non-invasive Tests for the Diagnosis and Monitoring of Non-Alcoholic Fatty Liver Disease.

Non-invasive test	Distinguish NASH from simple steatosis	Clinical context	Advantages	Limitations
Alanine Aminotransferase (ALT)	No	-Often used to identify individuals at risk for NAFLD. -Monitor response to therapy	-Widely available -Inexpensive	-Low sensitivity and specificity for NASH and fibrosis
Cytokeratin 18	Maybe	Research only, not available clinically	-May be able to distinguish those with NASH compared to simple steatosis, though more research is needed.	-Variability in cut-offs used in various studies -Not clinically available
NAFLD Fibrosis score	No	-Used to estimate an individual's risk for advanced fibrosis -Possible role in monitoring response to therapy	-Easy to calculate -Clinical information for the score is often available	-Large number of individuals fall in the indeterminate range -Different cut-off values needed for younger or older participants -Limited usefulness in the general population
Fibrosis-4	No	-Used to estimate an individual's risk for advanced fibrosis -Possible role in monitoring response to therapy	-Easy to calculate -Clinical information for the score is often available	-Large number of individuals fall in the indeterminate range -Various cut-offs used in studies -Limited usefulness in the general population
Vibration-Controlled Transient Elastography (VCTE; Fibroscan)	Maybe (in combination AST)	-Performs best at ruling out advanced fibrosis -Used to quantify liver fat -Possible role in monitoring response to therapy	-Performed in liver clinic - Simultaneously quantify fat (CAP) - Integrated quality control -Larger area of liver assessed -No prior experience with ultrasound required -portable options available	-Failure if narrow rib spaces -Failure if large ascites -Only measures CAP and LSM -Less cost effective if also need ultrasound
Supersonic shear imaging (SSI)	No	-Performs best at ruling out advanced fibrosis -Possible role in monitoring response to therapy	-Not impacted by rib spaces -Ok with large ascites -Evaluate other features of portal hypertension -Cost effective if also need ultrasound	-Performed in radiology -Does not quantify fat -Quality control not integrated -Smaller area of liver assessed -Lack of portability -Requires ultrasound expertise
Acoustic radiation force impulse (ARFI)	No	Same as SSI	Same as SSI	Same as SSI
Magnetic Resonance Elastography (MRE)	No	-Able to distinguish between fibrosis stages -Rules in or out advanced fibrosis -Possible role in monitoring response to therapy	-Overall best performance -Ok with large ascites -Can be easily performed with other techniques to quantify liver fat -Largest area of the liver assessed	-Performed in radiology -Performed at a limited number of centers -Quality control not integrated -Lack of portability Cost

NAFLD, Nonalcoholic Fatty Liver Disease; CAP, controlled attenuation parameter; LSM, liver stiffness measurement; AST, aspartate aminotransferase